New York, February 7, 2026, 05:48 EST — Market closed
- Pfizer finished Friday up 2.8%, closing at $27.22.
- The FDA put Hympavzi’s label expansion on an expedited review path, aiming for a decision by Q2 2026.
- TrumpRx launches its drug-discount program, dragging the spotlight back onto pricing pressure.
Pfizer Inc (PFE) closed out Friday at $27.22, notching a 2.8% gain. Shares fluctuated from $26.52 to $27.37 throughout the session, with volume hitting roughly 50.7 million shares.
Shares got a boost late in the week as Pfizer secured priority review status from the FDA on its supplemental bid for expanded Hympavzi use—a regulatory timer now ticking toward a second-quarter decision. Priority review knocks four months off the usual FDA review window. “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors,” said Michael Vincent of Pfizer. Contemporary Pediatrics
Drug pricing grabbed attention again as the Trump administration rolled out TrumpRx.gov. The site, which mostly features discounts via coupons or manufacturer links—not direct sales—went live with under 45 drugs, Reuters noted. More than 30 of those drugs were from Pfizer. “A small proportion of people may be able to find a better deal,” Vanderbilt health-policy professor Stacie Dusetzina said in an email. Reuters
Late Thursday, Pfizer rolled out details on its TrumpRx program, saying it covers over 30 medicines and could cut costs by up to 85% from list prices for people paying out of pocket, outside of insurance. Average savings land near 50% for a range of primary-care drugs and certain specialty brands. The company also pointed to its partnership with GoodRx, allowing patients to use coupons at most U.S. pharmacies or opt for home delivery. “Americans have shouldered a disproportionate share of the global cost of innovation,” Chief Executive Albert Bourla said. Pfizer
Pfizer said its supplemental Biologics License Application for Hympavzi aims to broaden use of the drug to include hemophilia A or B patients, age 6 and up, who have inhibitors. The filing also covers children ages 6 to 11 without inhibitors—those antibodies that can interfere with conventional factor replacement.
It’s not just Pfizer in the TrumpRx spotlight. According to Barron’s, the initiative covers around 40 drugs at discounted cash rates, with names like AstraZeneca, Pfizer, and Novo Nordisk in the mix. Wegovy, the weight-loss medication, stands out for its hefty price cut, Barron’s noted.
Pfizer shares climbed as U.S. equities rallied, with the S&P 500 tacking on close to 2% and the Dow clearing 50,000, according to MarketWatch data. Merck and Johnson & Johnson—both large-cap drugmakers—also closed in positive territory.
Pfizer topped fourth-quarter profit forecasts and stuck to its 2026 guidance earlier this week, yet shares slipped as fresh results from a trial obesity drug stoked concerns over side effects—a signal that the street is still sharp on pipeline delivery.
The weekend headline risk isn’t one-sided. According to Axios, drug-pricing expert Anna Kaltenboeck found that over half the drugs featured on TrumpRx already have less expensive generics on the market, which may hamper adoption and complicate margin calculations.
U.S. markets open again Monday, February 9. All eyes on Pfizer: can it stay above $27 as TrumpRx begins to roll out? Investors are also recalibrating their bets on Hympavzi’s label expansion. The FDA’s target decision lands in the second quarter of 2026—mark your calendars for that one.
